Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva(Sanford Burnham Prebys Medical Discovery Institute), Shuofeng Yuan(University of Hong Kong), Xin Yin(Sanford Burnham Prebys Medical Discovery Institute), Laura Martin‐Sancho(Sanford Burnham Prebys Medical Discovery Institute), Naoko Matsunaga(Sanford Burnham Prebys Medical Discovery Institute), Lars Pache(Sanford Burnham Prebys Medical Discovery Institute), Sebastian Burgstaller-Muehlbacher(Max Perutz Labs), Paul D. De Jesus(Sanford Burnham Prebys Medical Discovery Institute), Peter Teriete(Sanford Burnham Prebys Medical Discovery Institute), Mitchell Hull(Scripps Institution of Oceanography), Max W. Chang(University of California San Diego), Jasper Fuk‐Woo Chan(University of Hong Kong), Jianli Cao(University of Hong Kong), Vincent Kwok‐Man Poon(University of Hong Kong), Kristina M. Herbert(Sanford Burnham Prebys Medical Discovery Institute), Kuoyuan Cheng(National Cancer Institute), Tu-Trinh H. Nguyen(Scripps Institution of Oceanography), Andrey Rubanov(Sanford Burnham Prebys Medical Discovery Institute), Yuan Pu(Sanford Burnham Prebys Medical Discovery Institute), Courtney Nguyen(Sanford Burnham Prebys Medical Discovery Institute), Angela Choi(Icahn School of Medicine at Mount Sinai), Raveen Rathnasinghe(Icahn School of Medicine at Mount Sinai), Michael Schotsaert(Icahn School of Medicine at Mount Sinai), Lisa Miorin(Icahn School of Medicine at Mount Sinai), Marion Déjosez(New York Stem Cell Foundation), Thomas P. Zwaka(New York Stem Cell Foundation), Ko‐Yung Sit(University of Hong Kong), Luis Martínez‐Sobrido(Texas Biomedical Research Institute), Wen‐Chun Liu(Icahn School of Medicine at Mount Sinai), Kris M. White(Icahn School of Medicine at Mount Sinai), Mackenzie E. Chapman(Purdue University West Lafayette), Emma K. Lendy(Purdue University West Lafayette), Richard Glynne, Randy A. Albrecht(Icahn School of Medicine at Mount Sinai), Eytan Ruppin(National Cancer Institute), Andrew D. Mesecar(Purdue University West Lafayette), Jeffrey R. Johnson(Icahn School of Medicine at Mount Sinai), Christopher Benner(University of California San Diego), Ren Sun(University of California, Los Angeles), Peter G. Schultz(Scripps Institution of Oceanography), Andrew I. Su(Scripps Research Institute), Adolfo García‐Sastre(Icahn School of Medicine at Mount Sinai), Arnab K. Chatterjee(Scripps Research Institute), Kwok‐Yung Yuen(HKU-Pasteur Research Pole), Sumit K. Chanda(Sanford Burnham Prebys Medical Discovery Institute)
Cited by 856Open Access
Abstract
and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and ONO 5334. Notably, MDL-28170, ONO 5334 and apilimod were found to antagonize viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, their known pharmacological and human safety profiles will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.
Related Papers
No related papers found
Powered by citation graph analysis